Read one actual disclosure before using it
Scroll sideways to compare all columns. Select a heading to sort.
| COGENT BIOSCIENCES INC | COGT | COM | $45,307,638 | 1,170,740 | SH | None |
No matching rows. Clear the filter to see all records.
First displayed source row from Disclosed positions. The full bounded history and coverage notes remain below.
The displayed observation date is 2026-06-30 and its public availability date is 2026-08-15. Subtracting those calendar dates gives 46 days of disclosure lag. Historical public research can use the record from the availability date, rather than backdating knowledge to the observation date. The calendar-day difference does not assert an intraday publication time.
Read the amount together with its Unit and Option columns. A reported put or call position is not an option premium paid, and a quarterly holding is not a purchase made on its public filing date. Check every accession in the effective amendment lineage below: a retained holding can originate in an earlier filing rather than the latest linked amendment.
Open the linked original receipts to verify the row, then inspect a second record before drawing a pattern. This public filing observation supplies source evidence, not a completed copy-trading return.
Disclosed positions
Inspect all 35 displayed rows: Disclosed positions
Scroll sideways to compare all columns. Select a heading to sort.
| COGENT BIOSCIENCES INC | COGT | COM | $45,307,638 | 1,170,740 | SH | None |
| SYNDAX PHARMACEUTICALS INC | SNDX | COM | $40,550,300 | 1,855,000 | SH | None |
| CELLDEX THERAPEUTICS INC NEW | CLDX | COM NEW | $36,837,900 | 990,000 | SH | None |
| RELAY THERAPEUTICS INC | RLAY | COM | $27,415,370 | 1,465,279 | SH | None |
| VAXCYTE INC | PCVX | COM | $26,294,524 | 452,340 | SH | None |
| VERA THERAPEUTICS INC | VERA | CL A | $18,730,987 | 436,518 | SH | None |
| PHARVARIS N V | PHVS | COM | $18,180,435 | 525,750 | SH | None |
| VIRIDIAN THERAPEUTICS INC | VRDN | COM | $18,093,182 | 984,931 | SH | None |
| CYTOMX THERAPEUTICS INC. | CTMX | COM | $17,062,500 | 4,550,000 | SH | None |
| TRAVERE THERAPEUTICS INC | TVTX | COM | $16,622,606 | 292,600 | SH | None |
| LEGEND BIOTECH CORP | LEGN | SPONSORED ADS | $16,478,033 | 570,569 | SH | None |
| BEAM THERAPEUTICS INC | BEAM | COM | $16,347,920 | 476,338 | SH | None |
| CULLINAN THERAPEUTICS INC | CGEM | COM | $12,564,900 | 690,000 | SH | None |
| NURIX THERAPEUTICS INC | NRIX | COM | $11,159,600 | 460,000 | SH | None |
| KRYSTAL BIOTECH INC | KRYS | COM | $8,176,740 | 22,000 | SH | None |
| UNITED THERAPEUTICS CORP DEL | UTHR | COM | $8,127,450 | 15,000 | SH | None |
| SUMMIT THERAPEUTICS INC | SMMT | COM | $7,194,957 | 493,820 | SH | None |
| INSMED INC | INSM | COM PAR $.01 | $6,930,300 | 65,000 | SH | None |
| BIOCRYST PHARMACEUTICALS INC | BCRX | COM | $5,200,000 | 520,000 | SH | None |
| MBX BIOSCIENCES INC | MBX | COM | $5,023,200 | 91,000 | SH | None |
| PROTAGONIST THERAPEUTICS INC | PTGX | COM | $4,658,040 | 38,000 | SH | None |
| UROGEN PHARMA LTD | URGN | COM | $4,416,000 | 120,000 | SH | None |
| DBV TECHNOLOGIES S A | DBVT | SPONSORED ADS | $4,346,000 | 265,000 | SH | None |
| ALUMIS INC | ALMS | COM | $3,658,200 | 130,000 | SH | None |
| SUPERNUS PHARMACEUTICALS | SUPN | COM | $3,255,700 | 70,000 | SH | None |
| BIOMARIN PHARMACEUTICAL INC | BMRN | COM | $2,689,340 | 47,000 | SH | None |
| IMMUNOCORE HLDGS PLC | IMCR | ADS | $2,576,290 | 81,143 | SH | None |
| AMYLYX PHARMACEUTICALS INC | AMLX | COM | $2,011,520 | 112,000 | SH | None |
| ALECTOR INC | ALEC | COM | $1,809,000 | 900,000 | SH | None |
| SEPTERNA INC | SEPN | COM | $1,655,880 | 49,444 | SH | None |
| DESIGN THERAPEUTICS INC | DSGN | COM | $1,561,313 | 107,900 | SH | None |
| SUTRO BIOPHARMA INC | STRO | COM SHS | $1,063,628 | 32,037 | SH | None |
| WAVE LIFE SCIENCES LTD | WVE | SHS | $1,033,285 | 177,846 | SH | None |
| TYRA BIOSCIENCES INC | TYRA | COM | $638,800 | 20,000 | SH | None |
| ENGENE THERAPEUTICS INC | ENGN | COM | $363,300 | 210,000 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 0 positions are put or call entries.
The displayed holdings combine the effective filing versions listed here. The latest receipt linked below identifies the current projection version; it is not proof that every retained holding originated in that latest amendment. Inspect all effective accessions when verifying a position's source.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
| Effective SEC accession | Role in this view |
|---|---|
| 0001013594-26-000910 | Latest effective version |
No matching rows. Clear the filter to see all records.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.